July 2, 2024 – TenNor will present a series of posters on its investigational new drug rifaquizinone (TNP-2092) for the treatment of medical device infections at IDWeek 2024 to be held in Los Angeles, USA from October 16 to 20, 2024.

May 30, 2024 - May 28th is The International Day of Action for Women’s Healthcare to raise awareness for diseases and conditions that affect women’s physical and emotional health. The Journal of Medicinal Chemistry published a special Collection and showcased 17 articles that address the ongoing research dedicated to the unmet medical needs in women’s healthcare. TenNor’s article “Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens” was chosen for inclusion in the Collection and recognized in advancing research in women’s healthcare.

Suzhou China, February 14, 2024 – TenNor Therapeutics and the First Hospital of Jilin University jointly published a research article in The Lancet Infectious Diseases (Lancet ID), reporting the phase I/II clinical trial results of rifasutenizol (TNP-2198) for the treatment of Helicobacter pylori (H. pylori) infection. The journal also published a commentary on the research by leading experts in the field.

December 28, 2023 – The National Medical Products Administration (NMPA) approved TNP-2092 ointment to conduct a Phase I/II clinical trial for the treatment of diabetic foot infection (DFI).

Suzhou/China, December 12, 2023 – TenNor Therapeutics reports positive results from interim analysis of rifasutenizol (TNP-2198) phase III clinical trial for the treatment of Helicobacter pylori (H. pylori) infection.

Suzhou, China, October 13, 2023 – TenNor Therapeutics announced that its investigational new drug rifasutenizole (TNP-2198) for the treatment of H. pylori infection had been granted Fast Track designation by the FDA.

September 13, 2023 – TenNor Therapeutics announced that the National Medical Products Administration (NMPA) has approved the Phase I/II clinical trial of TNP-2092 for intra-articular injection (TNP-2092 IA) for the treatment of prosthetic joint infections (PJI).

Suzhou, China, May 20, 2023 – TenNor Therapeutics (Suzhou) Limited announced that its investigational new drug Rifasutenizole (TNP-2198) for the treatment of Helicobacter pylori infection has completed the first patient in (FPI) of a multi-center phase III trials in China.